Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate

Biochemical and Biophysical Research Communications

Volumn 391, Issue 3, 2010, Pages 1396-1399

  Yang, Pei Ming ^a   Lin, Jung Hsin ^a,b,c   Huang, Wen Yu ^a   Lin, Yi Chu ^a   Yeh, Shu Hao ^a   Chen, Ching Chow ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b RESEARCH CENTER FOR APPLIED SCIENCES   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Acetylation; Histone deacetylase; Histone deacetylase inhibitor; Methotrexate

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE LIKE PROTEIN; HISTONE H3; METHOTREXATE; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; FOLIC ACID ANTAGONISTS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; METHOTREXATE;

BACTERIA (MICROORGANISMS);

EID: 73949121803     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.072     Document Type: Article

References (15)

1. Olsen E.A. The pharmacology of methotrexate. J. Am. Acad. Dermatol. 25 (1991) 306-318
2. Lorico A., Toffoli G., Boiocchi M., Erba E., Broggini M., Rappa G., and D'Incalci M. Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5, 8-dideazafolic acid. Cancer Res. 48 (1988) 2036-2041
3. Lehrmann H., Pritchard L.L., and Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 86 (2002) 41-65
4. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
5. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552
6. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
7. Lin Y.C., Lin J.H., Chou C.W., Chang Y.F., Yeh S.H., and Chen C.C. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res. 68 (2008) 2375-2383
8. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
9. Dolinsky T.J., Czodrowski P., Li H., Nielsen J.E., Jensen J.H., Klebe G., and Baker N.A. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res. 35 (2007) W522-525
10. Bayly C.I., Cieplak P., Cornell W., and Kollman P.A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. 97 (1997) 10269-10280
11. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639-1662
12. Chang D.T., Oyang Y.J., and Lin J.H. MEDock: a web server for efficient prediction of ligand binding sites based on a novel optimization algorithm. Nucleic Acids Res. 33 (2005) W233-238
13. Stote R.H., and Karplus M. Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Proteins 23 (1995) 12-31
14. Dashwood R.H., Myzak M.C., and Ho E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?. Carcinogenesis 27 (2006) 344-349
15. Hider S.L., Bruce I.N., and Thomson W. The pharmacogenetics of methotrexate. Rheumatology (Oxford) 46 (2007) 1520-1524